Kezar Life Sciences Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018
Market Capitalization	62	69	481	822	242	77	451
Market Cap Growth	-	-85.69%	-41.42%	240.23%	214.65%	-82.98%	-
Enterprise Value	-121	-114	226	627	107	5	344
PE Ratio	-0.68	-0.68	-7.05	-15.04	-5.79	-2.19	-19.46
PS Ratio	8.84	9.84	-	-	-	-	-
PB Ratio	0.33	0.37	1.78	4.17	1.71	0.98	4.14
P/FCF Ratio	-0.83	-0.83	-7.97	-19.22	-6.50	-2.52	-20.59
P/OCF Ratio	-0.84	-0.84	-8.18	-19.36	-6.54	-2.57	-21.69
EV/Sales Ratio	-16.22	-16.22	-	-	-	-	-
EV/EBITDA Ratio	1.14	1.14	-3.42	-11.85	-2.65	-0.15	-15.28
EV/EBIT Ratio	1.13	1.13	-3.37	-11.52	-2.55	-0.14	-14.83
EV/FCF Ratio	1.36	1.36	-3.74	-14.68	-2.87	-0.16	-15.68
Debt / Equity Ratio	0.10	0.10	0.08	0.07	0.04	0.08	-
Debt / EBITDA Ratio	-0.19	-0.19	-0.32	-0.27	-0.14	-0.19	-
Debt / FCF Ratio	-0.23	-0.23	-0.35	-0.33	-0.15	-0.21	-
Quick Ratio	11.35	11.35	25.15	25.37	21.80	13.03	32.19
Current Ratio	11.66	11.66	25.98	25.77	22.48	13.52	32.91
Asset Turnover	0.03	0.03	0	0	0	0	0
Interest Coverage	-64.72	-64.72	-56.59	-342.58	-	-	-
Return on Equity (ROE)	-45.90%	-45.90%	-25.20%	-37.20%	-29.20%	-38.80%	-29.70%
Return on Assets (ROA)	-40.00%	-40.00%	-23.30%	-34.10%	-27.10%	-34.60%	-22.30%
Return on Capital (ROIC)	-53.96%	-53.96%	-24.44%	-25.91%	-29.33%	-44.24%	-22.73%
Earnings Yield	-164.64%	-147.92%	-14.18%	-6.65%	-17.28%	-45.71%	-5.14%
FCF Yield	-134.87%	-121.17%	-12.55%	-5.20%	-15.38%	-39.71%	-4.86%
Buyback Yield / Dilution	-7.70%	-7.70%	-27.69%	-19.90%	-130.58%	-85.92%	-1612.79%
Total Shareholder Return	-7.70%	-7.70%	-27.69%	-19.90%	-130.58%	-85.92%	-1612.79%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).